Bristol-Myers Squibb Company vs Amphastar Pharmaceuticals, Inc.: Strategic Focus on R&D Spending

R&D Spending: Bristol-Myers vs. Amphastar's Strategic Approaches

__timestampAmphastar Pharmaceuticals, Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 2014284270004534000000
Thursday, January 1, 2015370650005920000000
Friday, January 1, 2016411990004940000000
Sunday, January 1, 2017434150006411000000
Monday, January 1, 2018575640006345000000
Tuesday, January 1, 2019688530006148000000
Wednesday, January 1, 20206722900011143000000
Friday, January 1, 20216093200010195000000
Saturday, January 1, 2022747710009509000000
Sunday, January 1, 2023737410009299000000
Monday, January 1, 202411159000000
Loading chart...

In pursuit of knowledge

Strategic Focus on R&D Spending: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. From 2014 to 2023, Bristol-Myers Squibb Company and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. Bristol-Myers Squibb, a global biopharmaceutical giant, consistently allocated a significant portion of its resources to R&D, peaking in 2020 with a staggering 11% increase from the previous year. This strategic focus underscores their dedication to pioneering new treatments and maintaining a competitive edge. In contrast, Amphastar Pharmaceuticals, a smaller player, showed a steady yet modest increase in R&D spending, with a notable 26% rise from 2014 to 2023. This growth reflects their strategic intent to enhance their product pipeline and expand their market presence. The data highlights the diverse approaches these companies take in navigating the ever-evolving pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025